You are here

  • Home
  • Archive
  • Volume 13, Issue 6
  • Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

Article Text

Article menu
Download PDFPDF
REVIEW ARTICLES
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
  1. M. A. Bookman*,
  2. B. E. Greer† and
  3. R. F. Ozols*
  1. * Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  2. † Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, Washington
  1. Address correspondence and reprint requests to: Michael A. Bookman, MD, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111 USA. Email: ma_bookman{at}fccc.edu.

  1. Presented in part as ‘Carboplatin-Paclitaxel vs. Cisplatin-Paclitaxel and Update on GOG0182-ICON5’ 4th International Symposium, Advanced Ovarian Cancer: Optimal Therapy, Update. Valencia, Spain (28 February 03).

Abstract

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

  • carboplatin
  • ovarian cancer
  • paclitaxel
  • second-look

http://dx.doi.org/10.1136/ijgc-00009577-200311000-00002

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © 2003 Blackwell Science Ltd.